Recent Findings in N6 ‐Methyladenosine Modification and Significance in Pancreatic Cancer
Cancer Medicine · 2025
DOI: 10.1002/cam4.70934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2025. Verfasst von Tomoaki Hara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka, Jap…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenosine, RNA Processing, Post-Transcriptional. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takahashi Industrial and Economic Research Foundation, Mitsubishi Foundation, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Background
RNA modifications are widely detected in cells and are involved in RNA structural stabilization and regulation of gene expression. In cancer cells, RNA modifications are altered, resulting in abnormal expression of numerous genes and promoting cancer growth. N1‐methyladenosine (m 1 A), N6‐methyladenosine (m 6 A), N3‐methylcytosine (m 3 C), 5‐methylcytosine (m 5 C), 7‐methylguanosine (m 7 G), and N4‐acetylcytidine (ac 4 C) have been reported as RNA modifications affecting gene expression.
Aim
In this review, the function of m 6 A in pancreatic cancer is mainly described, and the current status and prospects of RNA modifications are discussed. Methodology We summarize recent reports on m 6 A writers METTL3, METTL5, METTL14, and METTL16; m 6 A readers IGF2BP1, IGF2BP2, IGF2BP3, YTHDF1, YTHDF2, and YTHDF3; and m 6 A erasers ALKBH5 and FTO.
Results
RNA modifications are written to the RNA by the writer, and the reader binds to the RNA modification, causing gene expression to increase or decrease. Gene expression is also regulated by the removal of RNA modifications by the eraser. Moreover, our recent investigation into m 6 A modifications in pancreatic cancer has led to the identification of several promising candidate biomarkers, highlighting the potential role of epitranscriptomic regulation in tumorigenesis.
Conclusion
These findings suggest that further exploration of RNA modification functions may facilitate the identification of novel biomarker and therapeutic target molecules for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka, Japan.
- Section for Computational and RNA Biology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.
- Prophoenix Division, Food and Life-Science Laboratory, IDEA Consultants, Inc., Osaka, Osaka, Japan.
- Kyowa-Kai Medical Corporation, Kawanishi, Hyogo and Osaka, Japan.
ORCID-Profile: Hideshi Ishii
Förderung
- Takahashi Industrial and Economic Research Foundation
- Mitsubishi Foundation
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Hara, T., Meng, S., Arao, Y., Saito, Y., Inoue, K., Rennie, S., Ofusa, K., Kitagawa, T., & Ishii, H. (2025). Recent Findings in N6 ‐Methyladenosine Modification and Significance in Pancreatic Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70934
Vancouver
Hara T, Meng S, Arao Y, Saito Y, Inoue K, Rennie S, et al. Recent Findings in N6 ‐Methyladenosine Modification and Significance in Pancreatic Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.70934
BibTeX
@article{Hara2025,
author = {Hara, Tomoaki and Meng, Sikun and Arao, Yasuko and Saito, Yoshiko and Inoue, Kana and Rennie, Sarah and Ofusa, Ken and Kitagawa, Toru and Ishii, Hideshi},
title = {Recent Findings in N6 ‐Methyladenosine Modification and Significance in Pancreatic Cancer},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70934}
}
EUVIMED